170 related articles for article (PubMed ID: 32614585)
1. Discovery of AB680: A Potent and Selective Inhibitor of CD73.
Lawson KV; Kalisiak J; Lindsey EA; Newcomb ET; Leleti MR; Debien L; Rosen BR; Miles DH; Sharif EU; Jeffrey JL; Tan JBL; Chen A; Zhao S; Xu G; Fu L; Jin L; Park TW; Berry W; Moschütz S; Scaletti E; Sträter N; Walker NP; Young SW; Walters MJ; Schindler U; Powers JP
J Med Chem; 2020 Oct; 63(20):11448-11468. PubMed ID: 32614585
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.
Sharif EU; Kalisiak J; Lawson KV; Miles DH; Newcomb E; Lindsey EA; Rosen BR; Debien LPP; Chen A; Zhao X; Young SW; Walker NP; Sträter N; Scaletti ER; Jin L; Xu G; Leleti MR; Powers JP
J Med Chem; 2021 Jan; 64(1):845-860. PubMed ID: 33399453
[TBL] [Abstract][Full Text] [Related]
3. Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production.
Du X; Moore J; Blank BR; Eksterowicz J; Sutimantanapi D; Yuen N; Metzger T; Chan B; Huang T; Chen X; Chen Y; Duong F; Kong W; Chang JH; Sun J; Zavorotinskaya T; Ye Q; Junttila MR; Ndubaku C; Friedman LS; Fantin VR; Sun D
J Med Chem; 2020 Sep; 63(18):10433-10459. PubMed ID: 32865411
[TBL] [Abstract][Full Text] [Related]
4. Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor.
Wang Y; Wang C; Zhu Y; Zhang Y; Chen B; Wu Y; Yao J; Miao Z
Bioorg Med Chem Lett; 2021 Feb; 34():127758. PubMed ID: 33359608
[TBL] [Abstract][Full Text] [Related]
5. Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface.
Rahimova R; Fontanel S; Lionne C; Jordheim LP; Peyrottes S; Chaloin L
PLoS Comput Biol; 2018 Jan; 14(1):e1005943. PubMed ID: 29377887
[TBL] [Abstract][Full Text] [Related]
6. An Exceptionally Potent Inhibitor of Human CD73.
Bowman CE; da Silva RG; Pham A; Young SW
Biochemistry; 2019 Aug; 58(31):3331-3334. PubMed ID: 31334635
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.
Beatty JW; Lindsey EA; Thomas-Tran R; Debien L; Mandal D; Jeffrey JL; Tran AT; Fournier J; Jacob SD; Yan X; Drew SL; Ginn E; Chen A; Pham AT; Zhao S; Jin L; Young SW; Walker NP; Leleti MR; Moschütz S; Sträter N; Powers JP; Lawson KV
J Med Chem; 2020 Apr; 63(8):3935-3955. PubMed ID: 32212732
[TBL] [Abstract][Full Text] [Related]
8. Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
Jeffrey JL; Lawson KV; Powers JP
J Med Chem; 2020 Nov; 63(22):13444-13465. PubMed ID: 32786396
[TBL] [Abstract][Full Text] [Related]
9. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017-present).
Nocentini A; Capasso C; Supuran CT
Expert Opin Ther Pat; 2021 Oct; 31(10):867-876. PubMed ID: 33909515
[TBL] [Abstract][Full Text] [Related]
11. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function.
Jin R; Liu L; Xing Y; Meng T; Ma L; Pei J; Cong Y; Zhang X; Ren Z; Wang X; Shen J; Yu K
Mol Cancer Ther; 2020 Nov; 19(11):2340-2352. PubMed ID: 32943546
[TBL] [Abstract][Full Text] [Related]
12. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells.
Romio M; Reinbeck B; Bongardt S; Hüls S; Burghoff S; Schrader J
Am J Physiol Cell Physiol; 2011 Aug; 301(2):C530-9. PubMed ID: 21593451
[TBL] [Abstract][Full Text] [Related]
13. A Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors of CD73 with Diverse Inhibition Modalities.
McManus J; He T; Gavigan JA; Marchand G; Vougier S; Bedel O; Ferrari P; Arrebola R; Gillespy T; Gregory RC; Licht S; Cheng H; Zhang B; Deng G
SLAS Discov; 2018 Mar; 23(3):264-273. PubMed ID: 29336194
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings.
Gong YP; Wan RZ; Liu ZP
Expert Opin Ther Pat; 2018 Feb; 28(2):167-171. PubMed ID: 29166791
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity.
Piovesan D; Tan JBL; Becker A; Banuelos J; Narasappa N; DiRenzo D; Zhang K; Chen A; Ginn E; Udyavar AR; Yin F; Paprcka SL; Purandare B; Park TW; Kimura N; Kalisiak J; Young SW; Powers JP; Schindler U; Sivick KE; Walters MJ
Mol Cancer Ther; 2022 Jun; 21(6):948-959. PubMed ID: 35405741
[TBL] [Abstract][Full Text] [Related]
16. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer.
Kim M; Min YK; Jang J; Park H; Lee S; Lee CH
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253638
[TBL] [Abstract][Full Text] [Related]
17. 2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.
Bhattarai S; Pippel J; Scaletti E; Idris R; Freundlieb M; Rolshoven G; Renn C; Lee SY; Abdelrahman A; Zimmermann H; El-Tayeb A; Müller CE; Sträter N
J Med Chem; 2020 Mar; 63(6):2941-2957. PubMed ID: 32045236
[TBL] [Abstract][Full Text] [Related]
18. Generation of Non-Nucleotide CD73 Inhibitors Using a Molecular Docking and 3D-QSAR Approach.
Bhujbal SP; Hah JM
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884548
[TBL] [Abstract][Full Text] [Related]
19. Extracellular adenosine produced by ecto-5'-nucleotidase (CD73) regulates macrophage pro-inflammatory responses, nitric oxide production, and favors Salmonella persistence.
Costales MG; Alam MS; Cavanaugh C; Williams KM
Nitric Oxide; 2018 Jan; 72():7-15. PubMed ID: 29108754
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S
Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
